To include your compound in the COVID-19 Resource Center, submit it here.

Five Prime ends antibody deal with Inhibrx

Five Prime Therapeutics Inc. (NASDAQ:FPRX) said it will terminate a 2015 deal with

Read the full 135 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE